Effects of Denosumab on Bone Mineral Density and Structural Damage in Patients with Osteoporosis and Rheumatoid Arthritis

Trial Profile

Effects of Denosumab on Bone Mineral Density and Structural Damage in Patients with Osteoporosis and Rheumatoid Arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2015

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jul 2015 New trial record
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top